Evaluating and Comparing the Adherence to Immediate- Release Tacrolimus (Prograf®) Versus Extended-Release Tacrolimus (Advagraf®) in Kidney Transplant Recipients
DOI:
https://doi.org/10.61882/ijkd.20.5.9515Keywords:
Tacrolimus, Kidney transplantation, Medication adherence, Prograf, AdvagrafAbstract
Introduction. This study compared adherence rates between immediate-release tacrolimus (Prograf®) and extended-release tacrolimus (Advagraf®) formulations in adult kidney transplant recipients in Iran. It is the first such comparison conducted in the country.
Methods. This prospective, observational cohort study was conducted among adult kidney transplant recipients in Shiraz, Iran. Adherence was assessed using the Basel Assessment of Adherence to Immunosuppressive Medications Scale (BAASIS) via self-report during face-to-face or telephone interviews at baseline (month zero) and six months. Intrapatient variability (IPV) of tacrolimus trough levels was calculated and compared between groups. The study also evaluated the risk factors associated with non-adherence and their potential impact on clinical outcomes.
Results. One hundred and ten patients (57 cases in the Prograf® group as twice daily; 53 cases in the Advagraf® group as once daily) completed six month follow-up. At month six, adherence rates were 63.16% in the Prograf® group versus 81.13% in the Advagraf® group (P = .04). Apart from correct dosing, all adherence parameters decreased significantly from baseline in both groups. The most common reason for non-adherence was forgetfulness in the Prograf® group and medication shortages/unavailability in the Advagraf® group. IPV was lower in the Advagraf® group (13.62 ± 8.07%) versus the Prograf® group (18.15 ± 13.18%), althoughthis difference was not statistically significant (P = .10). Conclusion. Extended-release tacrolimus (Advagraf®) was associated with significantly better adherence compared to the immediate-release formulation (Prograf®). These findings highlight the importance of once-daily formulations in enhancing adherence in postkidney transplantation care.
Downloads
References
1. Berquist RK, Berquist WE, Esquivel CO, Cox KL, Wayman KI, Litt IF. Non-adherence to post-transplant care: prevalence, risk factors and outcomes in adolescent liver transplant recipients. Pediatr Transplant. 2008;12(2):194- 200.
2.Zachciał J, Uchmanowicz I, Czapla M, Krajewska M, Banasik M. The Association between Psychosocial
and Age-Related Factors with Adherence to Immunosuppressive Therapies after Renal Transplantation. J Clin Med. 2022 24;11(9):2386.
3. Bowman LJ, Brennan DC. The role of tacrolimus in renal transplantation. Expert Opin Pharmacother.
2008;9(4):635-43.
4. Shafiekhani M, Shahabinezhad F, Niknam T, et al. Evaluation of the therapeutic regimen in COVID-19 in transplant patients: where do immunomodulatory and antivirals stand? Virol J. 2021;18(1):228.
5. Chisholm MA, Mulloy LL, DiPiro JT. Comparing renal transplant patients’ adherence to free cyclosporine
and free tacrolimus immunosuppressant therapy. Clin Transplant. 2005;19(1):77-82.
6. Godinas L, Dobbels F, Hulst L, et al. Once daily tacrolimus conversion in lung transplantation: A prospective study on safety and medication adherence. J Heart Lung Transplant. 2021;40(6):467-77.
7. Bentata Y. Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity. Artif Organs. 2020;44(2):140-52.
8. Javed M, Sanghera A, Khan AA, Nagpal R, Butler K,Hobill A, Gage A, Karst F, Needleman A, Hmun M, Thal
N, Shirling G, Fernando R, Jones G, Harber M, Evans RDR. Tacrolimus intrapatient variability and rejection are associated with inferior allograft outcomes after kidney transplantation. Front Nephrol. 2025 Dec 12;5:1666191. doi: 10.3389/fneph.2025.1666191.
9. Nafar M, Keshtkari S, Ziaie S, Firouzan A, Borumandnia N, Dalili N, Poorrezagholi F, Samadian F, Samavat S. Tacrolimus Intrapatient Variability on Graft Outcomes
in Adherent Renal Transplantation Patients: A Cross- Sectional Study. Iran J Kidney Dis. 2024 May;18(3):187- doi: 10.52547/54drw293.
10.Kuypers DR, Peeters PC, Sennesael JJ, Kianda MN, Vrijens B, Kristanto P, Dobbels F, Vanrenterghem Y, Kanaan N; ADMIRAD Study Team. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring. Transplantation. 2013 Jan 27;95(2):333-40.
11. Riani NW, Widiana IG, Kandarini Y. WCN26-8039 COMPARATIVE EFFICACY, SAFETY, AND ADHERENCE OF ONCE-DAILY VERSUS TWICE-DAILY TACROLIMUSIN ADULT KIDNEY TRANSPLANT RECIPIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS. KidneyInternational Reports. 2026 Apr 1;11(4).
12. Moradi O, Karimzadeh I, Davani-Davari D, Shafiekhani M, Sagheb MM. Pattern and associated factors of adherence to immunosuppressive medications in kidney transplant recipients at a referral center in Iran. Patient Prefer Adherence. 2019 8;13:729-38.
13. Inker LA, Eneanya ND, Coresh J, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021;385(19):1737-49.
14. Dobbels F, Berben L, Geest SD, et al. The psychometric properties and practicability of self-report instruments to identify medication nonadherence in adult transplant patients: a systematic review. Transplantation.2010;90(2):205-19.
15.Morais MC, Soares ME, Costa G, et al. Impact of tacrolimus intra-patient variability in adverse outcomes after organ transplantation. World J Transplant.2023;13(5):254-63.
16. Elnaem MH, Irwan NA, Abubakar U, Syed Sulaiman SA, Elrggal ME, Cheema E. Impact of Medication Regimen Simplification on Medication Adherence and Clinical Outcomes in Patients with Long-Term Medical Conditions. Patient Prefer Adherence. 2020;14:2135-45.
17. Eberlin M, Otto G, Krämer I. Increased medication compliance of liver transplant patients switched
from a twice-daily to a once-daily tacrolimus-based immunosuppressive regimen. Transplant Proc.
2013;45(6):2314-20.
18. Abedini S, Gøransson L, Cockburn E, Kilany S, Holdaas H. Immunosuppression Adherence in Stable Kidney Transplant Patients Converted From Immediate- to Prolonged-Release Tacrolimus in Clinical Practice: A Norwegian Study. Transplant Direct. 2018 Feb 2;4(2):e338.
19. Fellström B, Holmdahl J, Sundvall N, Cockburn E, Kilany S, Wennberg L. Adherence of Renal Transplant
Recipients to Once-daily, Prolonged-Release and Twice- daily, Immediate-release Tacrolimus-based egimens in a Real-life Setting in Sweden. Transplant Proc. 2018;50(10):3275-82.
20. Lehner LJ, Reinke P, Hörstrup JH, et al. Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study. Clin Transplant. 2018;32(1).
21. Paterson TS, Demian M, Shapiro RJ, Thornton WL. Impact of once-versus twice-daily tacrolimus dosing on medication adherence in stable renal transplant recipients: a Canadian single-center randomized controlled trial. CanJ Kidney Health Dis. 2019;6:2054358119867993.
22.Coste G, Lemaitre F. The Role of Intra-Patient Variabilityof Tacrolimus Drug Concentrations in Solid Organ Transplantation: A Focus on Liver, Heart, Lung and Pancreas. Pharmaceutics. 2022;14(2):379.
23.Larpparisuth N, Skulratanasak P, Vongwiwatana A, Premasathian N. Effect on Dosage Change and
Intrapatient Variability After Conversion From Twice-Daily to Once-Daily Tacrolimus Among Thai Kidney Transplant Patients With and Without CYP3A4/5 Inhibitors.Transplant Proc. 2019;51(8):2620-3.
24.Brunet M, Pastor-Anglada M. Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics. Pharmaceutics. 2022;14(9):1755.
25. Ganjali R, Ghorban Sabbagh M, Nazemiyan F,et al. Factors Associated With Adherence To Immunosuppressive Therapy And Barriers In Asian Kidney Transplant Recipients. Immunotargets Ther. 2019;8:53-62.
26. Krämer BK, Albano L, Banas B, et al. Efficacy of Prolonged- and Immediate-release Tacrolimus in
Kidney Transplantation: A Pooled Analysis of Two Large, Randomized, Controlled Trials. Transplant Proc.2017;49(9):2040-9.
27. Guirado L, Cantarell C, Franco A, et al. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. Am J Transplant. 2011;11(9):1965-71.
Downloads
Published
Data Availability Statement
The data supporting this study's findings are available from the corresponding author upon reasonable request.